相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading
David N. Louis et al.
BRAIN PATHOLOGY (2020)
Challenges to curing primary brain tumours
Kenneth Aldape et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Accelerated progression of IDH mutant glioma after first recurrence
Julie J. Miller et al.
NEURO-ONCOLOGY (2019)
The role of single-nucleotide polymorphism (SNPs) in toxicity of induction chemotherapy based on cisplatin and paclitaxel in patients with advanced head and neck cancer
Pedro De Marchi et al.
ORAL ONCOLOGY (2019)
Accuracy, Safety, and Reliability of Novel Phase I Trial Designs
Heng Zhou et al.
CLINICAL CANCER RESEARCH (2018)
Comparative review of novel model-assisted designs for phase I clinical trials
Heng Zhou et al.
STATISTICS IN MEDICINE (2018)
Novel Targeting of Transcription and Metabolism in Glioblastoma
Yu-Ting Su et al.
CLINICAL CANCER RESEARCH (2018)
Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL
Georg Karpel-Massler et al.
NATURE COMMUNICATIONS (2017)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma
Katelyn G. Ponder et al.
CANCER BIOLOGY & THERAPY (2016)
Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma
Jacob J. Mandel et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Bayesian optimal interval designs for phase I clinical trials
Suyu Liu et al.
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS (2015)
Influence of single-nucleotide polymorphisms on deferasirox Ctrough levels and effectiveness
J. Cusato et al.
PHARMACOGENOMICS JOURNAL (2015)
Zymosan induces NADPH oxidase activation in human neutrophils by inducing the phosphorylation of p47phox and the activation of Rac2: Involvement of protein tyrosine kinases, PI3Kinase, PKC, ERK1/2 and p38MAPkinase
Karama Makni-Maalej et al.
BIOCHEMICAL PHARMACOLOGY (2013)
Cyclin-dependent kinases 7 and 9 specifically regulate neutrophil transcription and their inhibition drives apoptosis to promote resolution of inflammation
A. E. Leitch et al.
CELL DEATH AND DIFFERENTIATION (2012)
TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties
K. C. Goh et al.
LEUKEMIA (2012)
Pol II waiting in the starting gates: Regulating the transition from transcription initiation into productive elongation
Sergei Nechaev et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2011)
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
James R. Perry et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation
Ulrich M. Zanger et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2008)
Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases
Gaetano Romano et al.
CELL CYCLE (2008)
Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects:: V.: Association of CYP1A2 1545 C>T polymorphism
A. K. Tiwari et al.
PHARMACOGENOMICS JOURNAL (2007)
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma
Antje Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT)
T. S. Armstrong et al.
JOURNAL OF NEURO-ONCOLOGY (2006)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Cancer pharmacogenetics: Polymorphisms, pathways and beyond
CM Ulrich et al.
NATURE REVIEWS CANCER (2003)
Pharmacogenomics: Unlocking the human genome for better drug therapy
HL McLeod et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2001)
分享论文
